The TAXUS ARRIVE 2 study is a multi-center safety and surveillance study designed to to compile safety surveillance and clinical outcomes data for the TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System in routine clinical practice and to identify low frequency TAXUS related clinical events.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
5,016
Drug Eluting Stent used to treat de novo coronary artery lesions.
Rate of TAXUS stent related cardiac events as classified by the Clinical Events Committee (CEC).
Time frame: 1-year post-implant procedure
Rate of TAXUS stent related cardiac events as classified by the CEC.
Time frame: within 30 days, 6 months and 2 years
Rate of target vessel related cardiac events as classified by the CEC.
Time frame: 30 days, at 6 months, at 1 and 2 years post-implant procedure
Rate of other TAXUS related events
Time frame: 30 days, 6 months, 1 and 2 years post-implant procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Scottsdale Healthcare
Scottsdale, Arizona, United States
Bakersfield Memorial Hospital
Bakersfield, California, United States
Desert Cardiology Consultants
Rancho Mirage, California, United States
Kaiser San Francisco
San Francisco, California, United States
Saint Vincent's Medical Center
Jacksonville, Florida, United States
Health First Clinical Research Institute
Melbourne, Florida, United States
Cardiology Consultants
Pensacola, Florida, United States
The Heart and Vascular Institute of Florida
St. Petersburg, Florida, United States
Idaho Cardiology Associates
Boise, Idaho, United States
Midwest Heart Foundation
Lombard, Illinois, United States
...and 43 more locations